Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial - Test2 - elhamkhani - TriplyDB

Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial

Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial

http://www.wikidata.org/entity/Q28469217

about

Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malariaedit The clinical efficacy of artemether/lumefantrine (Coartem)Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria Artemisinin-based combination therapy for treating uncomplicated malaria The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data Antimalarial efficacy of piperaquine-based antimalarial combination therapies: facts and uncertainties Curcumin-arteether combination therapy of Plasmodium berghei-infected mice prevents recrudescence through immunomodulation Polymorphisms in K13 and Falcipain-2 Associated with Artemisinin Resistance Are Not Prevalent in Plasmodium falciparum Isolated from Ugandan Children An economic evaluation of home management of malaria in Uganda: an interactive Markov model The use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria Malaria in Uganda: challenges to control on the long road to elimination: I. Epidemiology and current control efforts.Sustainable development of a GCP-compliant clinical trials platform in Africa: the malaria clinical trials alliance perspective.Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda.Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria.Epidemiological and clinical features of Plasmodium falciparum malaria in united nations personnel in Western Bahr el Ghazal State, South Sudan Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis.Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial.Update on the efficacy, effectiveness and safety of artemether-lumefantrine combination therapy for treatment of uncomplicated malaria.In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling.Efficacy, safety, and tolerability of three regimens for prevention of malaria: a randomized, placebo-controlled trial in Ugandan schoolchildren.Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy.Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso Does the Use of Dihydroartemisinin-Piperaquine in Treating Patients with Uncomplicated falciparum Malaria Reduce the Risk for Recurrent New falciparum Infection More Than Artemether-Lumefantrine?Protective efficacy of malaria case management and intermittent preventive treatment for preventing malaria mortality in children: a systematic review for the Lives Saved Tool Longitudinal study on Plasmodium falciparum gametocyte carriage following artemether-lumefantrine administration in a cohort of children aged 12-47 months living in Western Kenya, a high transmission area Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children A review of the effects of artemether-lumefantrine on gametocyte carriage and disease transmission Evaluation of recurrent parasitemia after artemether-lumefantrine treatment for uncomplicated malaria in children in western Kenya.Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination Cost-effectiveness of dihydroartemisinin-piperaquine compared with artemether-lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania.A phase III, randomized, non-inferiority trial to assess the efficacy and safety of dihydroartemisinin-piperaquine in comparison with artesunate-mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos.Malaria: an update on current chemotherapy.In vitro piperaquine susceptibility is not associated with the Plasmodium falciparum chloroquine resistance transporter gene Efficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children.Detection of persistent Plasmodium spp. infections in Ugandan children after artemether-lumefantrine treatment.Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children.Drug-Resistant Malaria: The Era of ACT.Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective study Comparative safety of artemether-lumefantrine and other artemisinin-based combinations in children: a systematic review

P2860

Q21032449-46F4939C-A4D7-44FF-B490-D6226D5FBB3C Q21034141-7221CAF0-1878-4441-B4D8-F00E7C8FD8D0 Q24201077-CAF855CE-1D76-455B-B839-79AE72A25F34 Q24241785-48F2F70D-473B-42BC-8525-0E1F70044E07 Q26822489-6E893677-8783-4763-AB09-DD0E00EF97BE Q26866187-5AE75958-599F-460D-9CD8-7CEFEA8F9E7F Q27310654-10E710B5-0B83-4A98-9464-D8BDCD0EF7EF Q27861962-5A12A66A-FBDF-4F27-9781-3E7B9BBD9230 Q28475337-588B712C-C3A7-4FE9-B596-B75723114670 Q28478579-A58F317A-4C28-4D71-89ED-EA7F8D19C097 Q30226671-11ACCE7E-057E-4ECD-89C0-B449F2F7AE18 Q30396940-86896654-E3C2-4BF5-81EF-B41CF6F343E7 Q33342827-0EC9A49C-EEFC-489B-9FF1-DDF8A977D91D Q33385477-7339D045-0C98-4B92-88E4-3AF0E8C3B911 Q33405647-E960FC1A-E182-46B9-B547-9DA121265C26 Q33489551-918EF67F-98C6-43CE-9718-C08CC56F64FC Q33516563-96DD8E5B-8BB1-4BA0-8B66-9D3C5750A3F9 Q33635019-0D51A0A9-F1DE-4E41-818C-413C6EB12640 Q33676088-E7928BF6-9416-4A5E-A8F5-21FABE48CDE0 Q33678483-07C6B8C0-B77B-4082-89AE-1FB7D9A0AC76 Q33728165-62FD7619-7B84-4F1B-B2F6-EBEB9E635ACD Q33733033-10F0CC21-3EDB-4981-87EB-4A995226FB74 Q33826359-80336380-3A0D-4BDA-93A5-7475BC29EB1A Q33874069-23017305-EAB4-49C9-A7A8-8C921E76EF20 Q33875677-D12877AC-94D0-45CF-B447-6DC337203CB0 Q33928116-7B9A96C8-E833-46B9-B09F-52B8A63F3768 Q33947834-25DE0F27-CB06-4F12-B1AB-B678A6435435 Q34020818-A936B899-2875-432A-85ED-7BEE5EDF1612 Q34087271-3E175507-FE73-470A-A6C7-ABD0A93BD3E7 Q34177472-257E329B-7612-49ED-B925-3AC03DBF9522 Q34227179-D5FA2937-8128-4181-A14D-81319474CB30 Q34341784-2DFA1264-E98E-4F11-BC47-FC2563D56FC9 Q34433106-83FAFB5A-6521-40FB-A292-954179A96297 Q34478084-974648AB-043E-49C0-8B33-778FAD965FD6 Q34562333-FA65E9F3-9DCF-49F9-9E46-ECD201C1CFC4 Q34629332-53DA2A63-A6EE-4332-88DE-BC6C3ACF43A8 Q34662803-D2443C5A-ADE6-4670-8A70-6BE928BFAB0C Q34681141-387BB9D3-5F5A-4F45-A5BC-5823C48FCB8B Q34728230-0455C2B8-E5DF-4644-B20A-4FD4AB92D9E4 Q35029488-51B3910E-8DA3-43A3-91AD-38FC424B5771

P2860

Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial

http://www.wikidata.org/entity/Q28469217

description

2007 nî lūn-bûn

@nan

2007 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Artemether-lumefantrine versus ...... of malaria: a randomized trial

@ast

Artemether-lumefantrine versus ...... of malaria: a randomized trial

@en

Artemether-lumefantrine versus ...... of malaria: a randomized trial

@nl

type

label

Artemether-lumefantrine versus ...... of malaria: a randomized trial

@ast

Artemether-lumefantrine versus ...... of malaria: a randomized trial

@en

Artemether-lumefantrine versus ...... of malaria: a randomized trial

@nl

prefLabel

Artemether-lumefantrine versus ...... of malaria: a randomized trial

@ast

Artemether-lumefantrine versus ...... of malaria: a randomized trial

@en

Artemether-lumefantrine versus ...... of malaria: a randomized trial

@nl

P1433

Q28469217-78E4B319-41AC-429A-9B22-E865BF832CAC

P1476

Q28469217-2A670400-38B4-420D-8ACD-F0E6C4FFA557

P2093

Q28469217-0636851E-4AB8-4583-BEF8-B60DC038CAEE

Q28469217-407EBC2D-1EF2-477D-82BA-07EFFEC411AC

Q28469217-6D6D69CE-076A-43F9-B78D-5CC168844724

Q28469217-8EC14B2C-7002-4EC4-9679-20E1C538B793

Q28469217-EA1DA3A1-30C0-4B42-8336-E990CC2583DA

P2860

Q28469217-21F70595-EDB2-4E77-A248-BF0B761B0898

Q28469217-2BA8CFBE-BD22-4B94-A5B3-9AF3F8EB214E

Q28469217-4F6E632A-E860-4C08-BBD7-840E7B2E4F28

Q28469217-541FEE80-6E5C-4D3F-90E4-C47634DFC6B4

Q28469217-57353BEB-5143-46C9-B1F2-803BCC1E443D

Q28469217-61898B2F-0C30-4A80-8C9D-A648F080552A

Q28469217-6D5AF944-8FF3-431B-B4F4-246E5183B971

Q28469217-7CF15B4C-47F2-4619-84B0-65E47A89AE90

Q28469217-96A46FE0-E583-4332-A7FB-E9FC8EE4C159

Q28469217-9BA9F417-EDD9-4E4E-A054-FDAB062DE963

P304

Q28469217-C14AAB59-97DB-4840-81E6-CA60DFE25F30

P31

Q28469217-F6508684-0BE3-47A1-A7E5-41DA34B3DEB3

P3181

Q28469217-4EE749A4-244F-45B6-9667-EB404D842840

P356

Q28469217-656A8104-48C1-4154-8DEC-5B52818A9DFB

P407

Q28469217-0B9B0684-AA27-4515-81EA-17C37C44BE14

P433

Q28469217-4A018FF6-AD11-4512-BA27-8D526E7878C5

P478

Q28469217-1AA642E7-7219-4E34-89AE-7BD09B4F1A71

P50

Q28469217-3AACF7AA-75E8-4153-9336-6A8129E785B9

Q28469217-4C4EF305-15DD-46CF-B293-395E9E0D8FE4

Q28469217-935816F8-DB51-4792-815E-0B401C3F2928

Q28469217-96473E4E-BE59-4ABF-AE0B-3B1E835A2695

Q28469217-A2A161C3-12A1-44DE-AD0D-5551580BB150

Q28469217-BA79A743-0893-49A1-9339-9ED1A44AE881

Q28469217-FC6FCE5D-10AF-4993-B41A-82E540C508C6

P577

Q28469217-EAD0FFB9-56D3-442D-BA77-0C49852D28ED

P698

Q28469217-9CC81C43-5BC7-4BC1-9EAA-FEBE551DACF5

P921

Q28469217-FB491F6C-415F-4E12-98BE-39961AA863DC

P932

Q28469217-D3389C0B-B877-4E26-89A8-148E5C4355D7

P3181

P356

JOURNAL.PCTR.0020020

P1433

PLOS Clinical Trials

P1476

Artemether-lumefantrine versus ...... of malaria: a randomized trial

@en

P2093

Adoke Yeka

http://www.w3.org/2001/XMLSchema#string

Ambrose O Talisuna

http://www.w3.org/2001/XMLSchema#string

Hasifa Bukirwa

http://www.w3.org/2001/XMLSchema#string

John B Rwakimari

http://www.w3.org/2001/XMLSchema#string

Myers Lugemwa

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa

Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda

Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda.

Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial.

Validation of microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections.

Trends in antimalarial drug deployment in sub-Saharan Africa.

WHO, the Global Fund, and medical malpractice in malaria treatment.

Artemether-lumefantrine for uncomplicated malaria: a systematic review.

Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.

Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria

P304

e20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3448491

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PCTR.0020020

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

François H Nosten

Bryan Greenhouse

Fred Wabwire-Mangen

Philip J Rosenthal

Sarah G. Staedke

P577

2007-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17525792

http://www.w3.org/2001/XMLSchema#string

P921

P932

1876597

http://www.w3.org/2001/XMLSchema#string